FTC Enforcement & Legal Health Claims for Mushroom Supplements
6 enforcement cases examined
A 2022 JAMA study found that the majority of dietary supplement products cited in FDA warning letters remained available for purchase, and the gap between receiving a warning and actually being removed from shelves is wider than most consumers realize.
Cohen et al., JAMA, 2022
Disease Claims
most common violation triggering FDA warning letters across 14 years of data (Brody 2016)
FTC Authority
governs advertising, not labeling; can issue consent orders and civil monetary penalties
Joint Letters
FTC and FDA coordinate enforcement via joint warning letters for the most serious violations
Cohen et al., JAMA, 2022
View as image ↗In 2020 and 2021, the FDA sent warning letters to at least three mushroom supplement companies claiming their products could treat or prevent cancer. The letters arrived. The companies acknowledged them. Some products kept selling. This is not an anomaly in FTC enforcement on mushroom supplement companies; it is the pattern documented by peer-reviewed research.
This article covers the real cases: specific named companies, the exact claims that triggered enforcement, and what the academic research tells us about whether these enforcement actions actually worked. For the broader regulatory framework that governs how mushroom supplements can legally be marketed, see How the FDA Regulates Mushroom Supplements: The DSHEA Framework.
Key Takeaways
- Multiple mushroom supplement companies received FDA warning letters between 2019 and 2021 for making cancer-related claims, including Desert Alchemist LLC, Entia Biosciences, and Half Hill Farm Inc
- A 2022 JAMA study found that the majority of dietary supplement products named in FDA warning letters remained available for purchase after the letters were issued, documenting a systemic gap between warning and removal (Cohen et al., 2022)
- Disease claims, particularly cancer, Alzheimer's, and diabetes, are the most common violation pattern in FDA warning letters, a finding consistent across 14 years of enforcement data (Brody 2016)
- The FTC regulates advertising claims (not labeling), and can pursue separate enforcement action including consent orders and civil penalties; Native Essence Herb Company faced FTC action specifically for maitake mushroom cancer cure claims in advertising
- In 2019, the FTC and FDA issued joint warning letters to supplement companies making Alzheimer's and cancer claims, representing a coordinated enforcement escalation
- International research confirms this is not a US-specific issue: a 2023 analysis of Italy's mushroom supplement market found widespread labeling inconsistencies and marketing claims exceeding the evidence base (Risoli et al., 2023)
The Warning That Didn't Work: What JAMA Found About Enforcement Gaps
In 2022, a team of researchers led by Pieter Cohen published a study in JAMA that examined what actually happens to dietary supplement products after the FDA sends them warning letters.[1]
The finding was counterintuitive. The majority of products cited in FDA warning letters remained available for purchase. Warning letters, it turned out, were a less effective removal mechanism than most consumers would assume.
The study exposed a structural reality of the post-market regulatory model that governs all dietary supplements under DSHEA (the Dietary Supplement Health and Education Act of 1994). Under DSHEA, supplements are sold until proven harmful or deceptively marketed; the government does not review them before they hit shelves. Warning letters are issued after complaints or reviews, but they create a compliance expectation, not an automatic recall requirement. The FDA can mandate a recall only under specific conditions, and warning letters do not automatically trigger those conditions.
For mushroom supplement consumers, this finding matters. A company that received a warning letter for claiming its turkey tail product had "anti-cancer effects" may well still be selling that product, under the same name, perhaps with slightly revised marketing.
How the FTC's Authority Differs from the FDA
The FDA's jurisdiction over dietary supplements covers labeling: the words on the bottle, the box, the insert. The FTC's jurisdiction covers advertising: what companies say in commercials, websites, social media, and marketing materials.
This split means that a company can theoretically receive an FDA warning letter about its product label and still be running deceptive advertising that the FDA has no direct authority to act on; the FTC would need to act separately. In practice, both agencies coordinate, especially for the most egregious violations.
The FTC's enforcement tools are more punitive than the FDA's warning letter system. When the FTC pursues a company directly, outcomes can include consent orders (legally binding agreements to stop specific practices), monetary civil penalties, and in extreme cases, permanent bans on making certain types of claims. The FDA's warning letter system, by contrast, typically gives companies time to respond and correct violations, which is why products often remain available during that window, and sometimes long after.
For a full breakdown of the FTC's regulatory architecture, including the 2022 update to its Health Products Compliance Guidance that increased the evidence standard for disease-benefit claims in advertising, see FTC Enforcement Against Mushroom Supplement Companies.
The Claim That Keeps Getting Companies Into Trouble: Cancer
A 14-year analysis of FDA warning letters found that disease claims are the single most common violation pattern.[2] Among disease categories, cancer is particularly prominent. This is not coincidental.
Cancer patients and caregivers are highly motivated buyers who actively search for treatments and complementary therapies. Supplements with cancer-adjacent language attract exactly this audience. And mushrooms have enough legitimate research on anti-cancer activity (mostly preclinical) that companies can reasonably argue their claims are grounded in the science, even when the science doesn't support the specific claims they're making.
The legal line is between a structure/function claim ("supports healthy cell function") and a disease claim ("treats cancer" or even more subtly "adjunct therapy for cancer treatment"). When companies use language that implies their product has effects on a named disease, that language crosses into disease claim territory, which requires FDA approval with significant scientific agreement, a standard no mushroom supplement currently meets.
For details on where that legal line sits and how companies cross it, see Health Claims on Mushroom Supplements: What's Legal and What's Not.
Three Companies, Three Warning Letters: 2020-2021
The following cases are drawn from FDA enforcement records. Each involves a mushroom supplement company that received a warning letter for health claims that crossed from structure/function territory into disease claim territory.
Desert Alchemist LLC (2020). The company's Fortify mushroom extract product was marketed with language describing it as an "adjunct therapy for cancer treatment." This framing, positioning the product as a companion to cancer treatment, is one of the clearest forms of disease claim language. "Adjunct therapy" implies the product has an established role in treating a specific disease, which requires clinical evidence and FDA approval the product did not have.
Entia Biosciences (2021). The company's maitake mushroom powder was marketed with claims describing "cancer fighting properties." Maitake has legitimate preclinical research on immune modulation and some animal model data on tumor response, but "cancer fighting properties" makes a specific therapeutic claim that the available evidence does not support for a dietary supplement product.
Half Hill Farm Inc (2020). The company's turkey tail product was marketed with "anti-cancer effects" language. Turkey tail (Trametes versicolor) is one of the more researched medicinal mushrooms, and PSK, a polysaccharide extract from turkey tail, is used as an approved drug adjunct in Japan. But in the US, that research does not make "anti-cancer effects" a legal structure/function claim; it makes it a disease claim requiring FDA approval.
All three cases involve different mushroom species and different marketing channels. All three triggered enforcement for the same category of violation: implying disease treatment or prevention without the regulatory approval required to make such claims.
When the FTC Acts Directly: Native Essence Herb Company
The distinction between FDA warning letters and FTC enforcement action is significant. FDA warning letters create an expectation of compliance and may be followed by additional enforcement steps. Direct FTC action against a company is a more formal and potentially more consequential proceeding.
Native Essence Herb Company faced FTC action specifically related to its maitake mushroom extract product. The company's advertising made claims about the product's ability to address cancer, positioning it in ways that FTC investigators determined constituted deceptive advertising under Section 5 of the FTC Act. The FTC's direct action authority (its ability to pursue civil penalties and consent orders) represents a different category of enforcement than the warning letter system, and its outcomes are typically more durable and harder for companies to sidestep by revising language and continuing to sell.
The case is notable as a mushroom-specific example of FTC direct action, distinguishing it from the broader FDA warning letter pattern where the majority of products remain available after letters are issued.
The 2019 Joint Enforcement Wave
The separation between FDA and FTC jurisdiction created coordination challenges that both agencies addressed through joint warning letters. In 2019, the FDA and FTC sent coordinated joint warning letters to supplement companies making claims related to Alzheimer's disease and cancer.
The joint letter approach signals escalated seriousness. When both agencies cosign a warning, the implicit message to the company is that both the labeling and the advertising are under scrutiny simultaneously, and that continued non-compliance could trigger enforcement from either direction.
The 2019 joint enforcement wave was part of a broader regulatory movement following a period in which both the cancer claim problem (documented consistently since at least 2016 by Brody's analysis) and the cognitive health claim problem had proliferated in the supplement market. Alzheimer's claims on supplements had become particularly common as the aging consumer population grew, and neither the FDA nor the FTC had found that warning letters alone were reliably shifting company behavior.
A Different Kind of Action: Blue Forest Farms (2025)
Not all enforcement actions against mushroom supplement companies are about health claim violations. Blue Forest Farms LLC received regulatory attention in 2025 related to its Amanita muscaria products, but the concern there was different in nature: the issue was safety classification and appropriate labeling for a species that contains psychoactive compounds (muscimol and ibotenic acid) distinct from psilocybin.
This case represents a separate regulatory category. The FDA's safety-based authority to remove products from the market is distinct from its authority to require label corrections for deceptive claims. When the concern is public safety rather than deceptive marketing, the enforcement pathway is different, and the speed of action can be faster.
Consumers encountering Amanita muscaria products should understand that the regulatory landscape for these products remains in active development, and that safety-focused enforcement (as opposed to claim-focused enforcement) may result in faster product removal than the warning letter pattern described in the Cohen 2022 study.
Beyond the United States: Italy's Mushroom Supplement Market
The pattern of marketing claims exceeding evidence is not a uniquely American regulatory failure. A 2023 analysis of Italy's mushroom supplement market found widespread labeling inconsistencies and marketing claims that exceeded the available evidence base.[3]
The Italian regulatory context differs from the US DSHEA framework, but the consumer-level outcome was similar: products on shelves making health benefit claims that outran what the underlying science supports, in a market where enforcement was insufficient to consistently correct the problem. The parallel matters because it suggests the issue is not simply a consequence of American regulatory weakness; it reflects market incentives that operate across different national regulatory systems.
The Gap Between Enforcement and Outcomes: What to Take From These Cases
The Cohen 2022 JAMA study finding is the right frame for interpreting these cases collectively.[1] Warning letters document violations. They create regulatory pressure. They may prompt some companies to revise their language. They do not reliably remove products or prevent continued deceptive marketing.
Three things follow from this for anyone who uses mushroom supplements:
First, the presence of a company in this article or in FDA enforcement records is not equivalent to the company or its products being dangerous. The violations described here are marketing violations: companies making claims their products are not approved to make. The products themselves may be exactly what they say they are in terms of ingredients.
Second, the absence of a company from enforcement records is not evidence that its marketing is accurate. The Brody 2016 14-year analysis of warning letter patterns found consistent violations across the industry.[2] The companies that received letters are not the only companies making impermissible claims; they are the companies that attracted enough attention to trigger a letter.
Third, understanding what types of claims are legally permissible (and which ones require regulatory approval that no mushroom supplement currently has) is the most reliable consumer protection mechanism available. For a practical breakdown of how to read mushroom supplement labels critically, see Structure/Function Claims vs. Disease Claims: The Legal Line. For how responsible companies navigate these rules, see How Mushroom Companies Navigate FDA and FTC Restrictions.
For the FDA's parallel enforcement activity, including FDA warning letters specifically for labeling violations, see FDA Warning Letters to Mushroom Companies: What Gets Flagged. For how the FDA-DSHEA framework shapes what companies can say at the structural level, see FDA and Mushroom Supplements: How DSHEA Shapes What Companies Can (and Can't) Say.
The Bottom Line
FDA warning letters have been issued to multiple mushroom supplement companies for cancer and disease claims, including Desert Alchemist LLC, Entia Biosciences, and Half Hill Farm Inc. The FTC pursued direct enforcement action against Native Essence Herb Company for maitake cancer claims in advertising. A 2022 JAMA study found that most supplement products remain available for purchase after warning letters, documenting a persistent gap between regulatory warning and actual market removal. All enforcement actions described are drawn from public FDA and FTC enforcement records.
Frequently Asked Questions
Sources & References
- 1. Source details for this reference are not yet available.
- 2. Source details for this reference are not yet available.
- 3. Source details for this reference are not yet available.